3B-O2-1505 PDF
Development of metabolome analysis based on mass spectrometry in clinical regions
Reliable disease biomarkers are essential for the realization of the advanced healthcare service in which preventive measures, early diagnosis, and treatments of diseases will be provided based on the individualized risk assessment. Metabolomics is a promising approach in the search for disease biomarkers. However, one of the challenges in the efforts for the clinical application of the metabolomics technology is a fact that the analytical results can vary significantly depending on the conditions of specimen collection and storage. On the other hand, MS-based global metabolomics (GMet) has been proven useful in the search for novel biomarkers, but has presented challenges in some aspects in its workflow as follows: through-put of sample processing, reproducibility of MS analysis, reliability of metabolite identification, and technical intricacy of data analysis. Therefore, in order to turn the MS metabolomics into a clinical practice, development of basic technologies to solve these problems is required. We established a high-throughput and fully automated sample-processing system for clinical specimens, and GMet protocols upon UPLC-Q-TOF/MS and LC-Q-FT/MS. We then performed MS metabolomics analysis of 500 participants of a population-based prospective cohort, and developed a GMet analysis software program using the data obtained thereof as a reference.